Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma

被引：0
|
作者：
Bruno, B
Ladetto, M
Mordini, N
Astolfi, M
Rotta, M
Cimolin, L
Compagno, M
Veneziano, L
Aitoro, G
Gallamini, A
Storb, R
Boccadoro, M
机构：
来源：
BONE MARROW TRANSPLANTATION | 2003年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S123 / S124
页数：2
相关论文
共 50 条
  • [41] Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant
    Beitinjaneh, Amer M.
    Saliba, Rima
    Bashir, Qaiser
    Shah, Nina
    Parmar, Simrit
    Hosing, Chitara
    Popat, Uday
    Anderlini, Paolo
    Dinh, Yvonne
    Qureshi, Sofia
    Rondon, Gabriela
    Champlin, Richard E.
    Giralt, Sergio A.
    Qazilbash, Muzaffar H.
    LEUKEMIA & LYMPHOMA, 2012, 53 (08) : 1525 - 1529
  • [42] Long-term follow-up of a comparison of non-myeloablative allografting with autografting for newly diagnosed myeloma
    Bruno, B.
    Sorasio, R.
    Patriarca, F.
    Mordini, N.
    Allione, B.
    Carnevale-Schianca, F.
    Giaccone, L.
    Resta, I.
    Festuccia, M.
    Rotta, M.
    Omede, P.
    Evangelista, A.
    Aglietta, M.
    Levis, A.
    Gallamini, A.
    Fanin, R.
    Palumbo, A.
    Storb, R.
    Ciccone, G.
    Boccadoro, M.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S17 - S17
  • [43] Significant graft-vs-myeloma (GvM) effect after non-myeloablative allogeneic transplantation in multiple myeloma (MM).
    Badros, A
    Tricot, G
    Morris, C
    Fox, M
    Munshi, N
    Spoon, D
    Martin, S
    Toor, A
    Zangari, M
    Fassas, A
    Desikan, R
    Anaissie, E
    Barlogie, B
    BLOOD, 2000, 96 (11) : 352B - 352B
  • [44] Patterns of minimal residual disease after high dose therapy in myeloma - A comparison of allografting and autografting.
    Haynes, AP
    Carter, GI
    Owen, R
    Davis, F
    Byrne, J
    Bybee, A
    Samsom, D
    Morgan, GJ
    Russell, NH
    BLOOD, 1997, 90 (10) : 995 - 995
  • [45] THYMIC OUTPUT AND T CELL RECONSTITUTION FOLLOWING NON-MYELOABLATIVE ALLOGRAFTING
    Bruno, B.
    Sfiligoi, C.
    Omede, P.
    Cena, S.
    Spagnolo, M.
    Testa, C.
    Cimolin, L.
    Resta, I
    Sorasio, R.
    Resta, I
    Giaccone, L.
    Boccadoro, M.
    HAEMATOLOGICA, 2008, 93 : S127 - S127
  • [46] Evaluation of Molecular Minimal Residual Disease in Multiple Myeloma: An Institutional Experience
    Hanley, Tim
    Clement, Parker
    Dickey, Laura
    Li, K. David
    MODERN PATHOLOGY, 2018, 31 : 519 - 520
  • [47] Evaluation of Molecular Minimal Residual Disease in Multiple Myeloma: An Institutional Experience
    Hanley, Tim
    Clement, Parker
    Dickey, Laura
    Li, K. David
    LABORATORY INVESTIGATION, 2018, 98 : 519 - 520
  • [48] Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma
    Fenk, R
    Ak, M
    Kobbe, G
    Steidl, U
    Arnold, C
    Korthals, M
    Hünerlitürkoglu, A
    Rohr, UP
    Kliszewski, S
    Bernhardt, A
    Haas, R
    Kronenwett, R
    HAEMATOLOGICA, 2004, 89 (05) : 557 - 566
  • [49] Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Follo Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma
    Campbell, Philip
    Das, Tongted
    Kipp, David
    Walker, Patricia A.
    Muirhead, Jenny
    Avery, Sharon
    Patil, Sushrut S.
    Curtis, David J.
    Schwarer, Anthony P.
    Kalff, Anna
    Spencer, Andrew
    BLOOD, 2013, 122 (21)
  • [50] Non-myeloablative allogeneic transplantation in patients with relapsed or refractory multiple myeloma.
    Gerull, S
    Hegenbart, U
    Goerner, M
    Benner, A
    Moehler, T
    Goldschmidt, H
    Ho, AD
    BLOOD, 2004, 104 (11) : 755A - 755A
12345